Potential conflict of interest: Dr. Fried has received research grants for clinical research and honoraria for speaking at symposia. He has no stock ownership, equity interest, or patent-licensing arrangement with Roche. Dr. Fried is a consultant for Roche. Dr. Piratvisuth advises, is on the speakers' bureau of, and received grants from Roche, Novartis, Schering-Plough, and GlaxoSmithKline. He also received grants from Bristol-Myers Squibb. Drs. Paik and Cooksley received grants from Roche. Dr. Lau received grants from Roche, Gilead, and Novartis. Dr. Marcellin is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche, Schering-Plough, Gilead, Bristol-Myers Squibb, GlaxoSmithKline, Vertex, Idenix-Novartis, Valeant, Human Genome Sciences, Coley Pharma, Cytheris, Intermune, Wyeth, and Tibotec.
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
Version of Record online: 7 JAN 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Volume 47, Issue 2, pages 428–434, February 2008
How to Cite
Fried, M. W., Piratvisuth, T., Lau, G. K. K., Marcellin, P., Chow, W.-C., Cooksley, G., Luo, K.-X., Paik, S. W., Liaw, Y.-F., Button, P. and Popescu, M. (2008), HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology, 47: 428–434. doi: 10.1002/hep.22065
- Issue online: 26 JAN 2008
- Version of Record online: 7 JAN 2008
- Accepted manuscript online: 7 JAN 2008 12:00AM EST
- Manuscript Accepted: 26 SEP 2007
- Manuscript Received: 28 FEB 2007
- Roche, Basel, Switzerland
- Unknown funding agency. Grant Numbers: K24 DK06614, RR000046
- 13NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1–46.
- 17Treatment of chronic hepatitis B infection using interferon. Med J Malaysia 2005; 60: 28–33..
- 20Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients. In: 41st Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria: April 26-30, 2006., , , , , , et al.
- 34Correlation between the prevalence of serum HBV DNA and immunoserologic HBV markers in the subjects with or without hepatitis. Immunol Invest 1992; 21275–21281., , , .
- 39Hepatitis B e antigen and antibody (HBeAg/anti-HBe). In: GeretyRJ, ed. Hepatitis B. Orlando, FL: Academic Press; 1985: 47–76., .